“NXT007, an Emicizumab-Based Therapeutic Antibody, Does Not Impair Activated Protein C’s Ability to Downregulate Activated Factor V in Factor VIII-Deficient or Factor V Leiden Plasma”

https://pubmed.ncbi.nlm.nih.gov/38115953

NXT007, an emicizumab-based therapeutic antibody, does not impair the ability of activated protein C to downregulate activated factor V in factor VIII-deficient or factor V Leiden plasma.